Page last updated: 2024-09-05

erlotinib hydrochloride and Neurofibromatosis 2

erlotinib hydrochloride has been researched along with Neurofibromatosis 2 in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Halpin, C; Harris, GJ; McClatchey, AI; O'Donnell, CC; Plotkin, SR; Singh, MA	1
Barker, FG; Batchelor, TT; Halpin, C; Loeffler, JS; McKenna, MJ; Plotkin, SR	1
Hamilton, J; Hong, DS; Ketonen, LM; Kurzrock, R; McCutcheon, IE; Slopis, J; Subbiah, V	1
Plotkin, SR; Terry, AR	1

Reviews

1 review(s) available for erlotinib hydrochloride and Neurofibromatosis 2

Article	Year
Chemotherapy: present and future. Otolaryngologic clinics of North America, 2012, Volume: 45, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Clinical Trials, Phase II as Topic; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Female; Follow-Up Studies; Forecasting; Humans; Magnetic Resonance Imaging; Male; Molecular Targeted Therapy; Neurofibromatosis 2; Neuroma, Acoustic; Quinazolines; Radiosurgery; Risk Assessment; Treatment Outcome	2012

Article

Year

Chemotherapy: present and future.

Otolaryngologic clinics of North America, 2012, Volume: 45, Issue:2

Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Clinical Trials, Phase II as Topic; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Female; Follow-Up Studies; Forecasting; Humans; Magnetic Resonance Imaging; Male; Molecular Targeted Therapy; Neurofibromatosis 2; Neuroma, Acoustic; Quinazolines; Radiosurgery; Risk Assessment; Treatment Outcome

2012

Trials

1 trial(s) available for erlotinib hydrochloride and Neurofibromatosis 2

Article	Year
Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Feb-10, Volume: 30, Issue:5 Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Child; Child, Preschool; Drug Synergism; Erlotinib Hydrochloride; Female; Humans; Indoles; Male; Molecular Targeted Therapy; Neurofibromatosis 2; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome; Valproic Acid; Vascular Endothelial Growth Factor A; Young Adult	2012

Article

Year

Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Feb-10, Volume: 30, Issue:5

Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Child; Child, Preschool; Drug Synergism; Erlotinib Hydrochloride; Female; Humans; Indoles; Male; Molecular Targeted Therapy; Neurofibromatosis 2; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome; Valproic Acid; Vascular Endothelial Growth Factor A; Young Adult

2012

Other Studies

2 other study(ies) available for erlotinib hydrochloride and Neurofibromatosis 2

Article	Year
Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy. Nature clinical practice. Oncology, 2008, Volume: 5, Issue:8 Topics: Audiometry, Pure-Tone; Auditory Threshold; Cochlear Implantation; Combined Modality Therapy; Ear Neoplasms; Erlotinib Hydrochloride; Hearing Loss, Sensorineural; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurofibromatosis 2; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Vestibular Diseases	2008
Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2010, Volume: 31, Issue:7 Topics: Adolescent; Adult; Antineoplastic Agents; Audiometry, Pure-Tone; Disease Progression; Erlotinib Hydrochloride; Female; Hearing Loss, Sensorineural; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurofibromatosis 2; Neuroma, Acoustic; Quinazolines; Speech Perception; Treatment Outcome; Young Adult	2010

Article

Year

Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy.

Nature clinical practice. Oncology, 2008, Volume: 5, Issue:8

Topics: Audiometry, Pure-Tone; Auditory Threshold; Cochlear Implantation; Combined Modality Therapy; Ear Neoplasms; Erlotinib Hydrochloride; Hearing Loss, Sensorineural; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurofibromatosis 2; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Vestibular Diseases

2008

Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2010, Volume: 31, Issue:7

Topics: Adolescent; Adult; Antineoplastic Agents; Audiometry, Pure-Tone; Disease Progression; Erlotinib Hydrochloride; Female; Hearing Loss, Sensorineural; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurofibromatosis 2; Neuroma, Acoustic; Quinazolines; Speech Perception; Treatment Outcome; Young Adult

2010